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The structure of a furin-antibody 
complex explains non-competitive 
inhibition by steric exclusion of 
substrate conformers
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Thomas Zögg2,†, Hans Brandstetter2 & Manuel E. Than1
Proprotein Convertases (PCs) represent highly selective serine proteases that activate their substrates 
upon proteolytic cleavage. Their inhibition is a promising strategy for the treatment of cancer and 
infectious diseases. Inhibitory camelid antibodies were developed, targeting the prototypical PC furin. 
Kinetic analyses of them revealed an enigmatic non-competitive mechanism, affecting the inhibition 
of large proprotein-like but not small peptidic substrates. Here we present the crystal structures of 
furin in complex with the antibody Nb14 and of free Nb14 at resolutions of 2.0 Å and 2.3 Å, respectively. 
Nb14 binds at a site distant to the substrate binding pocket to the P-domain of furin. Interestingly, no 
major conformational changes were observed upon complex formation, neither for the protease nor 
for the antibody. Inhibition of furin by Nb14 is instead explained by steric exclusion of specific substrate 
conformers, explaining why Nb14 inhibits the processing of bulky protein substrates but not of small 
peptide substrates. This mode of action was further supported by modelling studies with the ternary 
factor X-furin-antibody complex and a mutation that disrupted the interaction interface between furin 
and the antibody. The observed binding mode of Nb14 suggests a novel approach for the development 
of highly specific antibody-based proprotein convertase inhibitors.
Furin1 belongs to the family of the calcium-dependent proprotein convertases (PCs). These endoproteinases 
share structural homology of their catalytic domains with subtilisin. However, in contrast to subtilisin they are 
highly specific enzymes, activating a large number of secreted and membrane-associated secretory proteins by 
limited proteolysis. Substrate proteins include blood coagulation factors, hormones, growth factors, matrix met-
alloproteases as well as viral capsid proteins and bacterial toxins1,2. The classical PCs cleave after basic residue 
motifs, with furin preferentially recognising the motif R-X-K/R-R↓ (where “↓ ” represents the scissile peptide 
bond)3,4. Besides the subtilisin-like catalytic domain, all PCs require the so-called proprotein convertase domain 
(P-domain, for some family members also called Homo B domain) for catalytic activity5. The P-domain is located 
C-terminal to the catalytic domain and adopts a β -barrel-like fold. These proteases are also involved in a large 
number of pathologies, including bacterial and viral infections as well as cancer progression and metastasis2. 
Consequently, inhibitors of furin and other PCs are promising drug candidates6 and inhibitory molecules of a 
different chemical nature are currently being investigated in various labs7. Inhibitors of furin were successfully 
applied to inhibit the cell motility and invasiveness of cancer cells8, to impair carcinoma cell growth9 and to 
inhibit activation of HIV-1 glycoprotein gp16010. However, although inhibitors with high affinity have been devel-
oped11, obtaining specificity between the PC-family members remains challenging12. Most inhibitors target the 
substrate binding cleft of the PCs, which is highly conserved between these proteases13,14.
Crystal structures of inhibitor-bound murine4 and human11,15 furin as well as of the yeast homolog Kex2p16,17 
and modelling approaches13,14 gave hints as to how substrates and substrate-derived inhibitors bind to the PCs. 
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The commonly accepted notion is that the minimal working unit of the PCs consists of two consecutive struc-
tural units, the catalytic domain and the P-domain. PCs bind their cognate substrates and inhibitors via recog-
nition at several subsites at the catalytic domain, typically involving multiple tight contacts and hydrogen bonds. 
The P-domain is hereby closely associated with the catalytic domain and is essential for its stabilisation, but it 
does not seem to be involved in the ultimate subsite recognition. Antibodies can act as highly specific protease 
inhibitors18. Camelid antibodies (or their minimal active subfragments, the variable heavy chain (VH) domains; 
as isolated proteins often called VHH-fragments or “nanobodies”) as well as antigen binding fragments (Fabs) 
have been successfully applied to effectively inhibit pharmacological targets like human growth factor activator 
(HGFA)19, matriptase20, tumour necrosis factor-α -converting enzyme (TACE)21 or the trypsin-like serine pro-
tease HtrA-122. Nanobodies are highly versatile tools for research, diagnostic and therapeutic applications. They 
can be easily manipulated to change their half-life or to link them to another polypeptide like a toxin, a reporter, 
or a peptide inhibitor23. Structural analyses showed that antibody binding often blocks the active site cleft of tar-
get proteases (e.g. refs 19 and 20) or induces conformational changes and thus inhibits proteolysis allosterically 
(e.g. refs 24–26). Recently, nanobodies were developed which specifically target human and mouse furin27. They 
inhibited cleavage of diphtheria toxin and effectively protected cells from diphtheria-toxin-induced cytotoxic-
ity. Interestingly, only the turnover of protein substrates by furin was inhibited, whereas the hydrolysis of short 
fluorogenic peptides remained unaltered. As the kinetic analysis revealed a non-competitive mode of inhibition, 
it was concluded that these nanobodies do not seem to directly interfere with the catalytic mechanism or bind-
ing of substrates to the active site cleft27, calling for a structural characterization of their rather unusual mode of 
inhibition.
To unravel the binding epitope and the mode-of-action of the furin-inhibiting nanobody Nb14 we solved its 
structure in isolation as well as in complex with the target protease. Our structural and biochemical data explain 
its unusual inhibitory properties and suggest strategies for the future of inhibitor development.
Results
Co-crystal structure of furin and Nb14. We have crystallised the ternary complex of human furin with 
decanoyl-RVKR-chloromethylketone (RVKR-CMK) and the inhibitory camelid antibody Nb14. Even optimised 
crystals grew as needle clusters. Using a whole needle-cluster, initial diffraction data were obtained to a limit-
ing resolution of 2.9 Å at the synchrotron beamline BL14.1 of the Helmholtz-Zentrum Berlin (HZB) (Fig. S1a, 
Table S1). These data verified the presence of well diffracting mono-crystalline fragments within the mounted 
crystal bundles. The structure was solved by molecular replacement revealing the presence of two copies of the 
furin:RVKR-CMK:Nb14 complex in the asymmetric unit. To obtain better defined crystallographic data, rather 
small crystal fragments with approx. sizes of only 5 × 5 × 150 μ m3 were separated from these needle clusters and 
were used for single crystal diffraction data collection at the micro-focus beamline P14 at the European Molecular 
Biology Laboratory (EMBL) in Hamburg (Fig. S1b, Table S1). The latter dataset was subsequently used for refine-
ment of the furin:RVKR-CMK:Nb14 complex at 2.0 Å resolution at high quality with final R/Rfree factors of 
16.3/19.7% (Fig. 1, Table S1).
Nb14 was bound to the P-domain of furin rather than to the catalytic domain (Figs 1 and S2), which in 
addition was covalently inhibited by RVKR-CMK. The interaction interface at the P-domain is located distant 
to the active site cleft of the protease, involving amino acids Pro458-Asp460, Thr492-Asn496, Ala525-Asn529 
and Asn558-Thr564 of furin. The complementary region at the surface of Nb14 involves the amino acid seg-
ments Tyr32-Tyr35, Trp47-Arg53, Ser56-Asp59, Val98-Ala102 as well as Trp106. Assembly analysis with the 
PISA-server28 revealed an average covered surface area of ~685 A2. The interaction interface (~700 A2) is some-
what smaller than for the HGFA-inhibiting Fabs Ab58 (~900 A2) and Ab75 (~1000 A2). However, it corresponds 
well to the average size observed for protein-antigen complexes (varying from ~400 A2-~1000 A2 29) and to 
canonical kunitz-type trypsin inhibitors like amyloid precursor protein protease inhibitor domain (APPI or 
KPI, ~700 A2) and basic pancreatic trypsin inhibitor (BPTI, ~800 A2)30. The calculated average solvation free 
energy gain P-value (Δ iG-P) and complexation significance score (CSS) values of 0.199 and 0.293 of this inter-
face underline the significance of the observed interaction. All other molecular interactions, either mediated by 
non-crystallographic or crystallographic contacts, are classified as non-significant. An unusually high number 
of tyrosine side chains is found in the interaction interface of furin and Nb14, including Tyr32, Tyr35, Tyr109 
of Nb14 and Tyr560 of furin. These tyrosines form specific hydrogen bonds and contribute to the hydrophobic 
character of the surface. Analysis with the PISA server28 revealed an average solvation free energy gain (Δ iG) of 
− 28.5 kJ/mol, indicating a highly hydrophobic interface.
Mutation of the interaction interface abrogates inhibition by Nb14. To analyse the impact of the 
observed molecular contact, a point mutation was introduced to furin changing Thr562 into arginine. Thr562 is 
located at a central position of the interaction interface (inset in Fig. 1) Substitution by a bulky arginine sidechain, 
however, is expected to clash with the complementary surface of Nb14 and to disrupt its interaction with furin. 
The conservation of this amino acid in evolution is very low and its substitution should therefore not affect pro-
teolysis13. Indeed, we measured very similar specific activities of 53.3 ± 1.2 μ mol 7-Amino-4-methylcoumarin 
(AMC)/h/mg and 54.3 ± 0.5 μ mol AMC/h/mg for purified wild type (FurinWT) and mutated human furin 
(FurinT562R), respectively.
Next, we analysed the binding properties of FurinWT and FurinT562R in analytical gel permeation chromatog-
raphy (GPC) experiments. If an equimolar mixture of FurinWT and Nb14 is subjected to gel permeation chro-
matography, the proteins form the expected complex and co-elute in a single peak (Fig. 2a). Pre-mixed Nb14 
and mutant FurinT562R, however, elute as two separated peaks from the GPC-column (Fig. 2b). In conclusion, the 
mutation Thr562Arg at the interaction interface of furin disrupts complex formation with Nb14.
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Inhibition of furin by Nb14 can conveniently be monitored in limited proteolysis experiments with the furin 
substrate coagulation factor X31. Maturation of it requires cleavage by furin in between the catalytic domain and 
the EGF-2 domain. For cleavage assays we used the inactive Ser195Ala mutant (factor XS195A), showing largely 
reduced self-degradation compared to the wild type protease32. After incubation of both proteins a band shift 
Figure 1. Structure of the furin:RVKR-CMK:Nb14 complex. Human furin is shown as surface 
representation. The catalytic domain and the P-domain are coloured in yellow and brown, respectively. The dec-
RVKR-CMK inhibitor is shown as a ball and stick model with magenta carbons. Nb14 is displayed as a cartoon 
representation (blue) with the central disulphide bond highlighted as spheres. The inset shows a part of the 
interaction interface of furin and Nb14. The surface of the P-domain is shown as a partially transparent surface. 
The peptide stretch Gly561-Thr562-Leu563 is shown as a stick model. The 2Fo−Fc electron density composite 
omit map (green mesh) is contoured at 1.0 σ .
Figure 2. Interaction of Nb14 with FurinWT or FurinT562R. The UV280 absorption is shown as a function of 
the elution volume of the GPC column. Fractions under the peaks (black bars) were analysed by SDS-PAGE 
(insets). The premixed GPC sample was loaded as control to the SDS-PAGE (S). (a) GPC run of Nb14 and 
FurinWT, marked in the inset as open and filled arrowheads, respectively. (b) GPC run of Nb14 and FurinT562R, 
marked in the inset as open and filled arrowheads, respectively.
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from 42 to 38 kDa is observed (Fig. 3). FurinWT and FurinT562R essentially showed the same activity in the factor 
XS195A cleavage assay (Fig. 3). Apparently the introduced mutation affects neither the turnover of small peptidic 
substrates (see above) nor the proteolysis of protein substrates like factor XS195A. Cleavage of factor XS195A by 
FurinWT is largely reduced in the presence of 1 μ M Nb14 indicating inhibition of furin by the antibody (Fig. 3). 
FurinT562R, however, performs very similarly with and without Nb14 in the reaction mixture (Fig. 3).
Nb14 inhibits furin cleavage of large substrates via steric exclusion. An overall comparison of 
the human furin structure bound to Nb14 with isolated human furin (PDB-ID: 4RYD11) revealed a low average 
Cα-root mean square deviation (r.m.s.d.) of 0.32 Å. Furin is found in its catalytically active state forming a typical 
covalent complex with the chloromethylketone compound (Fig. S3a,b) that is very similar to non-covalently 
inhibited human furin15 and covalently inhibited mouse furin4. To investigate the effect of furin binding 
on the structure of the antibody, we also solved the structure of Nb14 in its free state (Table S1, Fig. S3c, see 
Supplementary Information for details). Also here, no significant structural alteration could be found as also 
indicated by the low Cα-r.m.s.d. of 0.20 Å (Fig. S3c).
Analysing the complex between furin and Nb14, we found that the shortest distance observed between Nb14 
(Asp62, side chain carboxylate) and the decanoylamide-C9 of the inhibitor measures approx. 19 Å. Canonical 
binding of peptides up to the S5 or S6 pockets is thus completely unperturbed by Nb14 and the placement of an 
elongated peptide chain to this region is sterically not hindered. In addition, the catalytic cleft and the active site 
of furin are clearly not blocked by the binding of Nb14, and its inactivity towards the cleavage of small peptidic 
substrates27 is perfectly conceivable.
Globular folded parts of substrate proteins do however show an additional level of access control to the active site 
of proteases, as they are largely sterically restricted from the substrate binding cleft. Therefore, the binding of protein-
aceous substrates to furin and their cleavage should only be possible if their overall conformation fits to the specific 
topology of the furin:Nb14 complex. This hypothesis was tested by means of modelling studies with the coagulation 
factor X (Figs 4 and S4). Proteolysis occurs here C-terminal to the recognition sequence Arg181-[P3]-Lys183-Arg184-↓ . 
The P1-P4 amino acids are estimated to bind in a similar conformation as observed for the RVKR-CMK inhibitor com-
plex. For our modelling studies this peptide stretch was aligned immediately C-terminal to the EGF2-domain of factor 
Xa (PDB-ID:2GD433), creating an extended factor Xa model, Xa* (catalytic domain including the furin recognition 
motif). The whole catalytic domain of factor Xa* was hereby treated as a rigid body, varying initially only the relative 
conformation of the amino acids between Thr178 and Arg181 and later also of the peptide stretch Cys174 to Glu180. 
Using this approach we modelled 13 different conformers of furin-bound factor Xa* that fit to the substrate binding 
pocket (Figs 4 and S4a). During modelling we realised that the conformation of Xa* is largely restricted by the deep sub-
strate binding cleft of furin and that the region between Thr178 and Arg181 requires a rather extended conformation to 
avoid steric clashes of furin and factor Xa. In presence of the Nb14 the conformational space is even more restricted and 
12 out of the 13 initially modelled Xa* conformers now show main-chain clashes with the antibody (Figs 4 and S4b). 
These clashes exclusively occur at sites distant to the active site cleft of furin. Consequently, the modelling studies sug-
gest a mode of action of Nb14 involving conformational restriction of the substrate. Binding and turnover of substrate 
proteins is still possible if this antibody is bound to furin, but now only a subset of all possible substrate conformers is 
still allowed to bind to and to be cleaved by the Nb14:furin complex.
Discussion
We have investigated the structural basis of inhibition of human furin by the highly specific inhibitory camelid 
antibody Nb1427. The structure of the furin-nanobody complex revealed a binding epitope at the P-domain dis-
tant to the active site cleft. These data imply a unique inhibition mechanism based on steric exclusion of certain 
conformers during substrate binding. Using a micrometre-sized X-ray beam and a high-precision diffractometer 
at the PETRAIII beamline P14 was hereby essential to solve the crystallographic structure as respective complex 
crystals could only be obtained in the form of small needles.
Figure 3. Proteolysis of factor XS195A by FurinWT or FurinT562R and its inhibition by Nb14. Factor XS195A was 
subjected to limited proteolysis by FurinWT or FurinT562R and analysed by SDS-PAGE. The bands of uncleaved 
factor XS195A (FX), cleaved factor XS195A (FX(cleaved)) and Nb14 are marked with arrowheads.
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The mode of action observed for Nb14 is largely different to other nanobodies that inhibit proteases by 
either blocking the active site cleft (e.g. refs 19 and 20) and/or by inducing conformational changes that inter-
fere with the catalytic mechanism (e.g. refs 24–26). It also suggests how inhibitory specificity between the 
highly homologous PCs can be achieved. Nb14 was shown to bind exclusively to furin27. Other PC family 
members, e.g. paired basic amino acid cleaving enzyme 4 (PACE4), proprotein convertase 1 (PC1) and propro-
tein convertase 2 (PC2), are not recognised by Nb1427. Interestingly it binds to a region of furin that was previ-
ously shown to have a low degree of conservation13, as the surface residues of the P-domain and especially the 
region around Thr562 are largely variable among the PC family members (Fig. S5). Notably, a point mutation 
in furin at Thr562 also completely abolished binding of Nb14. In contrast, peptide-based inhibitors and related 
small molecules directly interact with the core of the substrate binding pocket that is much more conserved 
between the different family members. The specificity of such compounds for individual PC-family members 
is correspondingly much lower12.
The structural features observed for the furin:RVKR-CMK:Nb14 complex also nicely explain the reported 
kinetic properties of Nb14. Binding of the nanobody occurs independently of the occupation of the substrate 
binding cleft. In previous studies we demonstrated that covalently and non-covalently inhibited furin showed 
very similar structures10. Therefore a structural influence of the bound inhibitor on the interaction interface of 
Nb14 is unlikely. As observed for the RVKR-CMK peptide, small fluorogenic substrates can bind to the protease 
and are hydrolysed with unaltered efficacy with and without bound Nb1427. Proteinaceous substrates, however, 
occupy a large space in the non-primed region of furin’s active site cleft as shown by modelling studies with 
factor X. In the furin:Nb14 complex especially, this space is restricted and thus specific substrate conformers are 
excluded from binding, reducing the effective substrate concentration. Previous studies have shown that the inhi-
bition strength of Nb14 indeed varied between substrates, e.g. a stronger inhibition was observed for glypican 3 
(GPC3) in comparison to tumour necrosis factor β (TGFβ )27. These data are very much in line with the structural 
Figure 4. Modelling of the furin-factor X enzyme-substrate complex. The furin:Nb14 complex is shown 
as surface representation and coloured in yellow (furin, catalytic domain), brown (furin, P-domain) and blue 
(Nb14). For modelling, the catalytic domain of factor X (cartoon representation) was linked to the N-terminus 
of the P1-P4 tetrapeptide (stick representation, magenta) of the co-crystallised RVKR-CMK inhibitor. (a) The 
one conformer that fits to the furin:Nb14 complex is coloured in magenta. (b) Conformers that do not fit to the 
furin:Nb14 complex are shown in grey.
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features of the furin:RVKR-CMK:Nb14 complex and with the modelled furin:Xa*:Nb14 enzyme substrate com-
plex. Our data suggest that inhibition by Nb14 also seems to depend on the specific steric properties of furin’s 
substrates.
In conclusion, Nb14 seems to facilitate the specific inhibition of furin over other PC family members. In 
addition, it probably also allows some specificity for certain substrate proteins or substrate classes. This potential 
substrate specificity of furin inhibiting antibodies must be characterised in detail by future studies. Nonetheless, 
this outstanding feature of Nb14 is of great interest for pharmacological applications. Potential therapeutic side 
effects might be reduced by targeting the conversion of only specific substrates rather than by complete inhibi-
tion of furin or even several PCs at the same time. Therapeutic antibodies might be raised to mainly inhibit only 
specific substrates of furin (e.g. hemagglutinin to treat acute influenza infections). Molecular tools are available 
(e.g. phage display34) allowing protein- and epitope-specific selection of antibodies. Therefore, similar molecules 
like Nb14 may be developed for inhibition of other PC family members (e.g. PACE4) or other protease classes.
Methods
The expression of camelid antibody Nb1427, human furin15 and recombinant coagulation factor XS195A 32 as well as 
the activity test of furin were described previously. Prior to crystallisation Nb14 and dec-RVKR-CMK-inhibited 
human furin were mixed at equimolar ratios and the resulting complex was purified by GPC. Details of the puri-
fication procedure and activity assays of the enzymes used are described in Supplementary Information.
The furin:RVKR-CMK:Nb14 complex (~9 mg/ml in in 10 mM Hepes, pH 7.5, 100 mM NaCl and 2 mM CaCl2) 
was crystallised in 0.1 M sodium acetate, pH 5.6, 16–18% PEG 3350. Crystals of isolated Nb14 were grown using 
a controlled dry-out procedure. Crystallisation drops (200 nl) of protein solution (10 mg/ml in 10 mM Hepes, 
pH 7.5, 100 mM NaCl and 1mM CaCl2) were pipetted without any reservoir solution. The plates were sealed and 
crystals appeared after several days and were stable for several weeks. Diffraction data were collected at BL 14.1 of 
BESSY-II, Helmholtz-Zentrum Berlin (HZB)35, and beamline P14, EMBL Hamburg (Table S1). Data processing 
was performed in XDS36 and programs of the CCP4-suite37. The structures were solved by molecular replace-
ment in PHASER38 using the structures of the isolated Nb14 and human furin (PDB-ID 4RYD11). COOT39 and 
PHENIX40 were applied for model building and refinement, respectively. MAIN41 was used for modelling of the 
furin:Nb14:factor X complex. Details of data collection, structure solution, model building and refinement pro-
cedures are described in Supplementary Information.
Analytical gel permeation chromatography runs were performed on a Superdex 200 5/150 GL column 
(GE Healthcare) in GPC buffer (10 mM Hepes, pH 7.5, 100 mM NaCl, 1 mM CaCl2) using an Aekta Micro FPLC 
system (GE Healthcare). The proteins were premixed at an equimolar ratio or mixed with GPC buffer for control 
runs at final concentrations of ~23μ M each and subsequently subjected to GPC at 0.2 ml/min. The peak fractions 
were analysed by SDS-PAGE. GPC binding assays were repeated three times.
Cleavage and inhibition assays with factor XS195A were performed in 100 mM Hepes, 5 mM CaCl, 0.5% 
TritonX100, pH7.0 at 25 °C in 20 μ l reaction setups. Samples contained 2.8 μ g recombinant factor XS195A, 4 ng 
FurinWT or FurinT562R and 1 μ M Nb14. For control samples the respective protein buffers were added to the 
reactions.
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